Pneumagen commits to clinical trial development for Covid-19
Pneumagen (Holdings) Ltd announced a £4m investment for the clinical development of Neumifil for the prevention and treatment of Covid-19.
Pneumagen (Holdings) Ltd announced a £4m investment for the clinical development of Neumifil for the prevention and treatment of Covid-19.
A new anti-viral drug developed by University spin out, Pneumagen, has had positive results in laboratory tests against Covid-19.